Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 21, 2014; 20(11): 2876-2887
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2876
Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality
Nobuyuki Toshikuni, Tomiyasu Arisawa, Mikihiro Tsutsumi
Nobuyuki Toshikuni, Tomiyasu Arisawa, Department of Gastroenterology, Kanazawa Medical University, Ishikawa 920-0293, Japan
Mikihiro Tsutsumi, Department of Hepatology, Kanazawa Medical University, Ishikawa 920-0293, Japan
Author contributions: Toshikuni N wrote this paper; Arisawa T and Tsutsumi M supervised the work.
Correspondence to: Nobuyuki Toshikuni, MD, Department of Gastroenterology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan. n.toshikuni@gmail.com
Telephone: +81-76-2862211 Fax: +81-76-2860892
Received: September 22, 2013
Revised: January 14, 2014
Accepted: February 17, 2014
Published online: March 21, 2014
Processing time: 177 Days and 1.7 Hours
Core Tip

Core tip: Liver cirrhosis (LC) is the critical stage of hepatitis C virus (HCV)-related chronic liver disease. Many studies of HCV-related LC patients have indicated that sustained virological response (SVR) after interferon therapy is highly associated with reductions in hepatic decompensation, hepatocellular carcinoma incidence, and mortality. Furthermore, direct-acting antiviral agents have shown excellent antiviral efficacy. Preliminary data have indicated that an interferon-free regimen achieved SVR for more than 50% of patients with LC due to HCV genotype 1. Branched-chain amino acid supplementation, improvement of insulin resistance, and the use of β-blockers for portal hypertension may also contribute to a reduction in liver-related complications.